4527 On Other Exchanges
Symbol
Exchange
4527 is not on other exchanges.

rohto pharmaceutical co ltd (4527) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROHTO PHARMACEUTICAL CO LTD (4527)

Related News

No related news articles were found.

rohto pharmaceutical co ltd (4527) Related Businessweek News

No Related Businessweek News Found

rohto pharmaceutical co ltd (4527) Details

Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. It offers eye care products, such as eye drops and contact lens; oral medicines comprising gastrointestinal medicines, Chinese herbal medicines, and supplements; dermal medications; regenerative medicines; and non-prescription medicines. The company also operates beauty counters that provide skin care products under the episteme, Obagi, and Hada-Labo brands, as well as beauty care treatments. In addition, it operates an online store, as well as a restaurant, an urban vegetable farm, and a relaxation salon. Rohto Pharmaceutical Co., Ltd. has a partnership agreement with Osaka University's Graduate School of Medicine for the commercialization of mesenchymal stem-cell-based regenerative treatments. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co., Ltd. in 1949. Rohto Pharmaceutical Co., Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

6,642 Employees
Last Reported Date: 06/22/16
Founded in 1899

rohto pharmaceutical co ltd (4527) Top Compensated Officers

Chairman of the Board of Directors and Chief ...
Total Annual Compensation: ¥160.0M
Compensation as of Fiscal Year 2016.

rohto pharmaceutical co ltd (4527) Key Developments

Rohto Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter and Year of Fiscal Year Ending March 31, 2017; Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Earnings Guidance for the Half Year and Full Year for the Year Ending March 31, 2017

Rohto Pharmaceutical Co., Ltd. provided dividend guidance for the second quarter and year of fiscal year ending March 31, 2017. For the second quarter, the company expects dividend of JPY 10 per share compared to JPY 10 per share a year ago. For the year, the company expects dividend of JPY 11 per share compared to JPY 10 per share a year ago. The company announced consolidated earnings results for the first quarter ended June 30, 2016. For the quarter, the company reported net sales of JPY 32,879 million against JPY 35,428 million a year ago. Operating income was JPY 2,217 million against JPY 1,857 million a year ago. Ordinary income was JPY 2,432 million against JPY 2,150 million a year ago. Profit attributable to owners of parent was JPY 1,373 million against JPY 1,328 million a year ago. Diluted net income per share was INR 12.02 against INR 11.64 a year ago. Profit before income taxes was JPY 1,996 million against JPY 2,110 million a year ago. For the half year ending March 31, 2017, the company reported net sales of JPY 75,000 million, operating income of JPY 7,000 million, ordinary income of JPY 6,800 million, profit attributable to owners of parent of JPY 4,300 million or net income of JPY 37.78 per share. For the year ending March 31, 2017, the company reported net sales of JPY 163,000 million, operating income of JPY 15,500 million, ordinary income of JPY 15,200 million, profit attributable to owners of parent of JPY 9,500 million or net income of JPY 83.47 per share.

Rohto Pharmaceutical and Osaka University Enter into Stem-Cell Research Partnership

Rohto Pharmaceutical and Osaka University's Graduate School of Medicine have entered into a research partnership focusing on accelerating the commercialisation of mesenchymal stem-cell-based regenerative treatments. Under the agreement, the two parties will use Rohto's stem cells to carry out research into serious heart failure, as well as evaluate pharmacological study models and conduct preclinical research. Depending on the outcome of the research, the partnership aims to conduct an investigator-initiated clinical trial, with the aim of receiving conditional approval for a regenerative treatment. Rohto also plans to consider future partnerships with Osaka University to explore other clinical applications of its mesenchymal stem cells.

Rohto Pharmaceutical Co., Ltd. Presents at 2016 Japan Kyoto Conference, Sep-08-2016

Rohto Pharmaceutical Co., Ltd. Presents at 2016 Japan Kyoto Conference, Sep-08-2016 . Venue: The Westin Miyako Kyoto, 1 Awataguchi Kachocho, Higashiyama-ku, Kyoto 605-0052, Japan.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4527 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4527.
View Industry Companies
 

Industry Analysis

4527

Industry Average

Valuation 4527 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ROHTO PHARMACEUTICAL CO LTD, please visit www.rohto.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.